Last update 05 Dec 2024

TGRX-1942

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
TGRX-1942
Target
PTK7
Mechanism
PTK7 inhibitors(Protein-tyrosine kinase 7 inhibitors)
Therapeutic Areas
NeoplasmsHemic and Lymphatic DiseasesRespiratory Diseases
Active Indication
Non-Small Cell Lung CancerRecurrent Hematologic MalignancyAdvanced Malignant Solid Neoplasm+ [1]
Inactive Indication
Leukemia
Originator Organization
Shenzhen TargetRx, Inc.Shenzhen TargetRx, Inc.Startup
Active Organization
Shenzhen TargetRx, Inc.Shenzhen TargetRx, Inc.Startup
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with TGRX-1942
NCT06484816 / Not yet recruitingPhase 1
A Dose Escalation and Expansion Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-1942 in Patients With Advanced Solid Tumor and/or Relapsed/Refractory Hematologic Malignancies
CTR20242037 / Not yet recruitingPhase 1
一项评价 TGRX-1942 片在晚期实体瘤和/或复发/难治性血液学肿瘤患者中的安全性、耐受性、药代动力学及初步有效性的剂量递增及扩展的Ⅰ期临床试验
[Translation] A Phase I dose-escalation and expansion clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of TGRX-1942 tablets in patients with advanced solid tumors and/or relapsed/refractory hematological tumors
100 Clinical Results associated with TGRX-1942
Login to view more data
100 Translational Medicine associated with TGRX-1942
Login to view more data
100 Patents (Medical) associated with TGRX-1942
Login to view more data
100 Deals associated with TGRX-1942
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 1-
Shenzhen TargetRx, Inc.Shenzhen TargetRx, Inc.Startup
31 Jul 2024
Recurrent Hematologic MalignancyPhase 1-
Shenzhen TargetRx, Inc.Shenzhen TargetRx, Inc.Startup
31 Jul 2024
Advanced Malignant Solid NeoplasmPhase 1
CN
Shenzhen TargetRx, Inc.Shenzhen TargetRx, Inc.Startup
11 Jun 2024
Hematologic NeoplasmsPhase 1
CN
Shenzhen TargetRx, Inc.Shenzhen TargetRx, Inc.Startup
11 Jun 2024
LeukemiaPreclinical
CN
Shenzhen TargetRx, Inc.Shenzhen TargetRx, Inc.Startup
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free